Non-invasive genetic test for improving migraine therapy decisions
Research type
Research Study
Full title
Validation study of a pharmacogenetic algorithm for preventative and acute migraine treatment: a questionnaire-based retrospective cohort study
IRAS ID
280681
Contact name
Kumeren Govender
Contact email
Sponsor organisation
Neurolytic Healthcare Ltd.
Duration of Study in the UK
2 years, 5 months, 10 days
Research summary
Headache is one of the most commonly reported neurological complaints in the world, of which migraine is the 3rd most common illness in the world and affects 1 in every 7 people. Furthermore, it typically affects those during the prime of life where migraines can lead to a severe cause of high disability and reduced quality of life. This study aims to validate the use of an algorithm using patient genetics, digital biomarkers and environmental factors to determine the optimal choice of treatment of migraine patients by correctly matching the most likely effective treatment. Participants aged 18-60 with a diagnoses of migraine since 1 January 2017 will be eligible. The study will be conducted remotely and not involve any physical visits. Participants will be asked to complete an initial questionnaire, post us a saliva sample, and optionally wear a smartwatch that integrates to our downloadable migraine app for up to 6 months. The study duration will be from June 2020 to December 2022. The research is funded by Neurolytic Healthcare Ltd.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
20/SC/0294
Date of REC Opinion
10 Aug 2020
REC opinion
Further Information Favourable Opinion